James Hadfield
Director ctDNA & Epigenomics Oncology Translational Medicine AstraZeneca
Seminars
Wednesday 1st April 2026
Accelerating Clinical Timelines with Submission-Ready MRD Regulatory Infrastructure
10:10 am
- Benefits of Ultrasensitive ctDNA: Discover how NeXT Personal utilises whole genome sequencing and tumor-informed personalised panels, tracking up to 1,800 high-quality variants to optimise signal-to-noise ratios in plasma timepoints
- Evidence-Based Drug Development: Hear from James Hadfield of AstraZeneca to discuss specific use cases and key highlights from the CALLA Phase III trial in cervical cancer
- Streamlined Global Regulatory Strategies: Discover a "least burdensome" regulatory approach for drug development
